Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-06-25

Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating erenumab (AMG 334) versus placebo for migraine prevention has completed with posted results in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • erenumab (erenumab)

Snippet

Sponsor: Amgen | Conditions: Migraine | Phase 3 | Status: COMPLETED | Results posted: 2018-06-25